Press "Enter" to skip to content

Tiny Sienna is calling in Cowen as shares continue to languish long after a severe trial setback – Endpoints News

admin 0

Tiny Sienna is calling in Cowen as shares continue to languish long after a severe trial setback  Endpoints News

Sienna needs to raise cash to pay for a planned Phase III pivotal of their new lead drug SNA-120, a TrkA inhibitor for psoriasis, which the biotech says won’t get …

“bladder cancer” – Google News

(Visited 1 times, 1 visits today)

Leave a Reply

Your email address will not be published. Required fields are marked *